Page last updated: 2024-10-19

niacin and Coronary Artery Stenosis

niacin has been researched along with Coronary Artery Stenosis in 9 studies

Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.

Research Excerpts

ExcerptRelevanceReference
"In a three-year, double-blind trial, 160 patients with coronary disease, low HDL cholesterol levels and normal LDL cholesterol levels were randomly assigned to receive one of four regimens: simvastatin plus niacin, vitamins, simvastatin-niacin plus antioxidants; or placebos."9.09Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. ( Alaupovic, P; Albers, JJ; Bolson, EL; Brown, BG; Chait, A; Cheung, MC; Dowdy, AA; Fisher, LD; Frohlich, J; Marino, EK; Morse, JS; Zhao, XQ, 2001)
"Niacin-treated subjects compared to untreated subjects had significantly less change in mean coronary stenosis (0."6.78Effects of niacin on glucose levels, coronary stenosis progression, and clinical events in subjects with normal baseline glucose levels (<100 mg/dl): a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), HDL-Atherosclerosis Treatment ( Brown, BG; Isquith, D; Muñoz, L; Phan, BA; Shadzi, P; Triller, M; Zhao, XQ, 2013)
"We examined the effects of simvastatin-niacin and antioxidant vitamins on changes in high-density lipoprotein (HDL) subpopulations and alterations in coronary artery stenosis, as assessed by angiography."5.10Change in alpha1 HDL concentration predicts progression in coronary artery stenosis. ( Asztalos, BF; Batista, M; Brown, GB; Cox, CE; Dallal, GE; Horvath, KV; Morse, JS; Schaefer, EJ, 2003)
"In a three-year, double-blind trial, 160 patients with coronary disease, low HDL cholesterol levels and normal LDL cholesterol levels were randomly assigned to receive one of four regimens: simvastatin plus niacin, vitamins, simvastatin-niacin plus antioxidants; or placebos."5.09Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. ( Alaupovic, P; Albers, JJ; Bolson, EL; Brown, BG; Chait, A; Cheung, MC; Dowdy, AA; Fisher, LD; Frohlich, J; Marino, EK; Morse, JS; Zhao, XQ, 2001)
"Niacin-treated subjects compared to untreated subjects had significantly less change in mean coronary stenosis (0."2.78Effects of niacin on glucose levels, coronary stenosis progression, and clinical events in subjects with normal baseline glucose levels (<100 mg/dl): a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), HDL-Atherosclerosis Treatment ( Brown, BG; Isquith, D; Muñoz, L; Phan, BA; Shadzi, P; Triller, M; Zhao, XQ, 2013)

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19901 (11.11)18.7374
1990's0 (0.00)18.2507
2000's4 (44.44)29.6817
2010's4 (44.44)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Zambon, A2
Zhao, XQ3
Brown, BG5
Brunzell, JD2
Kotsia, AP1
Rangan, BV1
Christopoulos, G1
Coleman, A1
Roesle, M1
Cipher, D1
de Lemos, JA1
McGuire, DK1
Packer, M1
Banerjee, S1
Brilakis, ES1
Dobiásová, M1
Frohlich, J2
Sedová, M1
Cheung, MC2
Phan, BA1
Muñoz, L1
Shadzi, P1
Isquith, D1
Triller, M1
Asztalos, BF1
Batista, M1
Horvath, KV1
Cox, CE1
Dallal, GE1
Morse, JS2
Brown, GB1
Schaefer, EJ1
BISIANI, M1
FRESIA, P1
GENOVESE, E1
MORTARI, A1
Hokanson, JE1
Motulsky, AG1
Chait, A1
Fisher, LD1
Dowdy, AA1
Marino, EK1
Bolson, EL1
Alaupovic, P1
Albers, JJ1
Freedman, JE1

Clinical Trials (8)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effect of Alirocumab on Saphenous Vein Graft Atherosclerosis: The Alirocumab for Stopping Atherosclerosis Progression in Saphenous Vein Grafts (ASAP-SVG) Pilot Trial[NCT03542110]Phase 446 participants (Actual)Interventional2018-08-04Terminated (stopped due to Withdrawal of medication and funding support by Sponsor)
Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis: The Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE-SVG) Pilot Trial[NCT01221402]Phase 238 participants (Actual)Interventional2010-10-31Completed
Carotid Plaque Composition by Magnetic Resonance Imaging During Lipid Lowering Therapy[NCT00715273]Phase 4217 participants (Actual)Interventional2001-05-01Completed
Heartmatters Challenge - First Responders[NCT03322046]185 participants (Actual)Observational2013-10-08Completed
High Density Lipoprotein Subspecies and Coronary Disease[NCT00005676]2,700 participants (Actual)Observational2000-04-30Completed
[NCT00000553]Phase 30 participants Interventional1994-09-30Completed
ARBITER 6: ARterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6 - HDL and LDL Treatment Strategies in Atherosclerosis (HALTS)[NCT00397657]Phase 4400 participants (Anticipated)Interventional2006-11-30Terminated (stopped due to Independent steering committee has stopped the trial based on results of a prespecified, blinded interim analysis. It was not stopped due to safety concerns.)
HDL Increased Plaque Stabilization in the Elderly[NCT00127218]Phase 3145 participants (Actual)Interventional2003-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Annualized LRNC Volume Change in Carotid Plaque Composition, as Assessed by MRI

"The primary endpoint of this study is carotid plaque lipid composition identified by MRI. The determination of plaque lipid content for each carotid artery will be performed using the automated interactive system. These measurements will be performed from the MRI scans at four time points blinded to time sequence of MRI examinations, patient treatment, lipid levels and clinical course.~Volume Measurements: Contours were placed around the lumen, outer-wall boundaries, and plaque features of carotid artery. (Arterial wall area) = (outer-wall area) - (lumen area). Volume calculated as: area x 2 mm (slice thickness). Tissue volume/wall volume x (100%) is presented as percentage. Annualized change presented mm^3/year (for volume) and as percentage change/year." (NCT00715273)
Timeframe: Measured at Years 1, 2, and 3

Interventionmm^3/year (Mean)
1 - Single Therapy Group-4.6
2 - Double Therapy Group-15.1
3 - Triple Therapy Group-9.4

Annualized LRNC and Wall Volume Changes in Carotid Plaque Composition, as Assessed by MRI

"The primary endpoint of this study is carotid plaque lipid composition identified by MRI. The determination of plaque lipid content for each carotid artery will be performed using the automated interactive system. These measurements will be performed from the MRI scans at four time points blinded to time sequence of MRI examinations, patient treatment, lipid levels and clinical course.~Volume Measurements: Contours were placed around the lumen, outer-wall boundaries, and plaque features of carotid artery. (Arterial wall area) = (outer-wall area) - (lumen area). Volume calculated as: area x 2 mm (slice thickness). Tissue volume/wall volume x (100%) is presented as percentage. Annualized change presented mm^3/year (for volume) and as percentage change/year." (NCT00715273)
Timeframe: Measured at Years 1, 2, and 3

,,
Interventionpercentage change/year (Mean)
LRNC changeWall Volume change
1 - Single Therapy Group-1.6-0.6
2 - Double Therapy Group-3.6-1.4
3 - Triple Therapy Group-2.8-1.2

Composite of Cardiovascular Endpoints: Number of Participants With Cardiovascular Disease Death, Non-fatal Heart Attack, Stroke, and Worsening Ischemia Requiring Medical Interventions

Any cardiovascular events such as death from any cause, nonfatal myocardial infarction, stroke, and revascularization procedures (PCI or CABG) due to unstable ischemia will be recorded and verified. (NCT00715273)
Timeframe: Measured at Years 3, 4, and 5

,,
InterventionParticipants (Count of Participants)
Composite Measured at Year 3Composite Measured at Year 4 (cumulative)Composite Measured at Year 5 (cumulative)
1 - Single Therapy Group679
2 - Double Therapy Group61111
3 - Triple Therapy Group799

Changes in Plaque Architecture and Composition Directly Measured by Magnetic Resonance Imaging (MRI) in the Aorta and Carotid Arteries

The primary endpoint is Changes in plaque architecture and composition directly measured by magnetic resonance imaging (MRI) in the aorta and carotid arteries. (NCT00127218)
Timeframe: 18 months

Interventionpercentage of internal carotid artery (Mean)
Niacin Plus Statin7
Placebo Plus Statin5

Multiple Combined Events ( Cardiovascular and Cerebrovascular Events as Well as Myocardial Revascularization)

Cerebrovascular events (newly diagnosed) such as Stroke and Myocardial revascularization (specifically coronary artery bypass grafting, percutaneous coronary interventions, carotid endarterectomy) were recorded (NCT00127218)
Timeframe: 18 months

InterventionParticipants (Count of Participants)
Any Statin Plus Niacin6
Any Statin Plus Placebo2

Trials

6 trials available for niacin and Coronary Artery Stenosis

ArticleYear
Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis: Insights from the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE-SVG) Pilot Trial.
    The Journal of invasive cardiology, 2015, Volume: 27, Issue:10

    Topics: Aged; Atherosclerosis; Coronary Angiography; Coronary Artery Bypass; Coronary Stenosis; Delayed-Acti

2015
Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis: Insights from the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE-SVG) Pilot Trial.
    The Journal of invasive cardiology, 2015, Volume: 27, Issue:10

    Topics: Aged; Atherosclerosis; Coronary Angiography; Coronary Artery Bypass; Coronary Stenosis; Delayed-Acti

2015
Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis: Insights from the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE-SVG) Pilot Trial.
    The Journal of invasive cardiology, 2015, Volume: 27, Issue:10

    Topics: Aged; Atherosclerosis; Coronary Angiography; Coronary Artery Bypass; Coronary Stenosis; Delayed-Acti

2015
Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis: Insights from the Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE-SVG) Pilot Trial.
    The Journal of invasive cardiology, 2015, Volume: 27, Issue:10

    Topics: Aged; Atherosclerosis; Coronary Angiography; Coronary Artery Bypass; Coronary Stenosis; Delayed-Acti

2015
Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography.
    Journal of lipid research, 2011, Volume: 52, Issue:3

    Topics: Antioxidants; Apolipoproteins B; Atherosclerosis; Cholesterol; Coronary Angiography; Coronary Stenos

2011
Effects of niacin on glucose levels, coronary stenosis progression, and clinical events in subjects with normal baseline glucose levels (<100 mg/dl): a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), HDL-Atherosclerosis Treatment
    The American journal of cardiology, 2013, Feb-01, Volume: 111, Issue:3

    Topics: Blood Glucose; Carotid Stenosis; Cholesterol, HDL; Cholesterol, LDL; Coronary Angiography; Coronary

2013
Change in alpha1 HDL concentration predicts progression in coronary artery stenosis.
    Arteriosclerosis, thrombosis, and vascular biology, 2003, May-01, Volume: 23, Issue:5

    Topics: Aged; Antioxidants; Apolipoprotein A-I; Apolipoprotein A-II; Coronary Stenosis; Disease Progression;

2003
Change in alpha1 HDL concentration predicts progression in coronary artery stenosis.
    Arteriosclerosis, thrombosis, and vascular biology, 2003, May-01, Volume: 23, Issue:5

    Topics: Aged; Antioxidants; Apolipoprotein A-I; Apolipoprotein A-II; Coronary Stenosis; Disease Progression;

2003
Change in alpha1 HDL concentration predicts progression in coronary artery stenosis.
    Arteriosclerosis, thrombosis, and vascular biology, 2003, May-01, Volume: 23, Issue:5

    Topics: Aged; Antioxidants; Apolipoprotein A-I; Apolipoprotein A-II; Coronary Stenosis; Disease Progression;

2003
Change in alpha1 HDL concentration predicts progression in coronary artery stenosis.
    Arteriosclerosis, thrombosis, and vascular biology, 2003, May-01, Volume: 23, Issue:5

    Topics: Aged; Antioxidants; Apolipoprotein A-I; Apolipoprotein A-II; Coronary Stenosis; Disease Progression;

2003
Genetically determined apo B levels and peak LDL density predict angiographic response to intensive lipid-lowering therapy.
    Journal of internal medicine, 2006, Volume: 259, Issue:4

    Topics: Adult; Analysis of Variance; Apolipoproteins B; Colestipol; Coronary Angiography; Coronary Stenosis;

2006
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.
    The New England journal of medicine, 2001, Nov-29, Volume: 345, Issue:22

    Topics: alpha-Tocopherol; Antioxidants; Apolipoproteins; Ascorbic Acid; beta Carotene; Cardiovascular Diseas

2001
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.
    The New England journal of medicine, 2001, Nov-29, Volume: 345, Issue:22

    Topics: alpha-Tocopherol; Antioxidants; Apolipoproteins; Ascorbic Acid; beta Carotene; Cardiovascular Diseas

2001
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.
    The New England journal of medicine, 2001, Nov-29, Volume: 345, Issue:22

    Topics: alpha-Tocopherol; Antioxidants; Apolipoproteins; Ascorbic Acid; beta Carotene; Cardiovascular Diseas

2001
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.
    The New England journal of medicine, 2001, Nov-29, Volume: 345, Issue:22

    Topics: alpha-Tocopherol; Antioxidants; Apolipoproteins; Ascorbic Acid; beta Carotene; Cardiovascular Diseas

2001
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.
    The New England journal of medicine, 2001, Nov-29, Volume: 345, Issue:22

    Topics: alpha-Tocopherol; Antioxidants; Apolipoproteins; Ascorbic Acid; beta Carotene; Cardiovascular Diseas

2001
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.
    The New England journal of medicine, 2001, Nov-29, Volume: 345, Issue:22

    Topics: alpha-Tocopherol; Antioxidants; Apolipoproteins; Ascorbic Acid; beta Carotene; Cardiovascular Diseas

2001
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.
    The New England journal of medicine, 2001, Nov-29, Volume: 345, Issue:22

    Topics: alpha-Tocopherol; Antioxidants; Apolipoproteins; Ascorbic Acid; beta Carotene; Cardiovascular Diseas

2001
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.
    The New England journal of medicine, 2001, Nov-29, Volume: 345, Issue:22

    Topics: alpha-Tocopherol; Antioxidants; Apolipoproteins; Ascorbic Acid; beta Carotene; Cardiovascular Diseas

2001
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.
    The New England journal of medicine, 2001, Nov-29, Volume: 345, Issue:22

    Topics: alpha-Tocopherol; Antioxidants; Apolipoproteins; Ascorbic Acid; beta Carotene; Cardiovascular Diseas

2001

Other Studies

3 other studies available for niacin and Coronary Artery Stenosis

ArticleYear
Effects of niacin combination therapy with statin or bile acid resin on lipoproteins and cardiovascular disease.
    The American journal of cardiology, 2014, May-01, Volume: 113, Issue:9

    Topics: Bile Acids and Salts; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Stenosis

2014
[Capacity of iproniazid to inhibit in vivo the coronary constrictor effect of pitressin].
    Minerva medica, 1958, Nov-14, Volume: 49, Issue:91

    Topics: Antidiuretic Hormone Receptor Antagonists; Coronary Stenosis; Coronary Vessels; Humans; IgA Vasculit

1958
Antioxidant versus lipid-altering therapy--some answers, more questions.
    The New England journal of medicine, 2001, Nov-29, Volume: 345, Issue:22

    Topics: Antioxidants; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Coronary Stenosis; Drug Therapy,

2001